Frame Therapeutics is committed to revolutionizing the treatment of cancer by guiding the immune system toward Frame neoantigens. We are working on tailored cancer immunotherapies, customized based on the Frame neoantigens specifically encoded by each patient's tumor genome. Our approach is built on the fusion of two recent groundbreaking advancements in genomics and immunotherapy. Initially, the rapid differentiation between healthy cell genomes and tumor cell genomes is made possible by the next generation Whole Genome sequencing technology.
Frame Cancer Therapeutics
Headquarters
Netherlands